Treated Hypertension has No Influence on the Efficacy of Alendronate in the Therapy of Postmenopausal Osteoporosis: A Non-Randomized, Non-Blind, Controlled Prospective Study
Doerte Matziolis*, 1, Monika Drewke2, Georg Matziolis1, Carsten Perka1
Identifiers and Pagination:Year: 2011
First Page: 27
Last Page: 31
Publisher ID: TOORTHJ-5-27
Article History:Received Date: 22/4/2010
Revision Received Date: 12/7/2010
Acceptance Date: 25/11/2010
Electronic publication date: 7/1/2011
Collection year: 2011
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Changes in hormone metabolism during menopause are involved in the development of osteoporosis and arterial hypertension. A mutual influence of these two clinical pictures is evident on the basis of pathophysiological factors.
In this study, we investigated whether a drug therapy of hypertension influences the efficacy of a bisphosphonate (alendronate) in the treatment of postmenopausal osteoporosis. For this purpose, 60 female patients were enrolled in the study, 30 of them on drug treatment for hypertension in addition to requiring treatment for osteoporosis, while the control group was only suffering from osteoporosis.
Bone density was measured at the start of the study and 6 months after therapy (QCT).
A significant increase in bone density was demonstrated in both groups, while a difference between the groups could not be seen.
Treated arterial hypertension does not have a negative influence on the treatment of postmenopausal osteoporosis with alendronate. Rather, the concomitant treatment of these two clinical pictures would appear to make sense, in order to reduce morbidity and mortality.